Administrative Core

行政核心

基本信息

项目摘要

Administrative Core (Core A) SUMMARY The Administrative Core, led by Dr. Jeffrey Myers and Dr. Vlad Sandulache, and supported by the Center Administrator Dr. Toyin Babarinde, is an indispensable component of the Houston Center for Acquired Resistance Research (H-CARR). The overall objective of the Administrative Core (Core A) is to provide critical centralized support to the H-CARR and ensure seamless interactions and integration between the three projects and cores within the center as well as the broader ARTNet community. Core A is designed to monitor research activity and provide stable and continuous leadership that guides future scientific directions for this Research Center. Core A will leverage the wide-ranging scientific, research related experience of the Center Advisory Group in critical decision-making steps. The Administrative Core will ensure an emphasis on basic mechanistic and translational research and facilitate interdisciplinary and inter-project integration, including assistance in the establishment of collaborations with other ARTNet centers as well as the U24 ARTNet Coordinating Data and Management Center (ARTNet CDMC U24) and NCI staff. Core A will also have overall responsibility for fiscal and budgetary management of the H-CARR, including the employment of key personnel to ensure a highly qualified, well trained, managed, and diverse work force that will enable cost-effective and efficient use of resources. This Core will also monitor scientific integrity and overall compliance with all institutional, state, federal, and NCI regulations and requirements, as well as quality assurance for data integrity. The strength of Core A rest in its well-developed structure of intra-programmatic, intra-institutional, and external advisors who are all dedicated to support Core A Leaders through ongoing review, advice, and periodic meetings and recommendations to ensure robust scientific performance and progress toward the agreed upon programmatic goals. Under the direction of the Core A Leaders, Core A will also provide support and infrastructure for research, facilitate clear and open communications among all H-CARR investigators, provide a centralized resource for regulatory monitoring and compliance activities, and perform scheduled reviews of project and core activities and progress towards their goals. Under the direction of the Core A Leaders, Core A will also provide support and infrastructure for research, facilitate clear and open communications among all H-CARR investigators, engage in regulatory monitoring to optimize the successful outcome of the basic mechanistic and preclinical/translational research in resistance to drug therapy in head and neck cancer.
行政核心(核心 A)摘要 行政核心,由 Jeffrey Myers 博士和 Vlad Sandulache 博士领导,并得到中心的支持 管理员 Toyin Babarinde 博士是休斯顿获得性耐药中心不可或缺的组成部分 研究(H-CARR)。管理核心(核心 A)的总体目标是提供关键的集中化服务 支持 H-CARR 并确保三个项目和核心之间的无缝交互和集成 在中心以及更广泛的 ARTNet 社区内。核心 A 旨在监控研究活动和 提供稳定和持续的领导,指导该研究中心未来的科学方向。核 A 将利用中心咨询小组在关键领域广泛的科学、研究相关经验 决策步骤。行政核心将确保强调基本机制和转化 研究并促进跨学科和项目间的整合,包括协助建立 与其他 ARTNet 中心以及 U24 ARTNet 协调数据和管理中心的合作 (ARTNet CDMC U24)和 NCI 工作人员。核心 A 还将全面负责财政和预算 H-CARR 的管理,包括雇用关键人员,以确保拥有高素质、良好的团队 训练有素、管理良好、多元化的劳动力队伍将能够实现资源的成本效益和高效利用。这 Core 还将监控科学完整性以及对所有机构、州、联邦和 NCI 的总体合规性 法规和要求,以及数据完整性的质量保证。 Core A 的优势在于其 完善的项目内、机构内和外部顾问结构,他们都致力于 通过持续审查、建议以及定期会议和建议来支持核心 A 领导者,以确保 强劲的科学表现和在实现商定的计划目标方面取得的进展。在 的指导下 核心 A 领导者、核心 A 还将为研究提供支持和基础设施,促进清晰和开放 所有 H-CARR 研究人员之间的沟通,为监管监控和 合规活动,并对项目和核心活动及其进展情况进行定期审查 目标。在核心 A 领导人的指导下,核心 A 还将为研究提供支持和基础设施, 促进所有 H-CARR 调查人员之间清晰、开放的沟通,参与监管监控 优化耐药性的基本机制和临床前/转化研究的成功成果 头颈癌的药物治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jeffrey Nicholas Myers其他文献

Jeffrey Nicholas Myers的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jeffrey Nicholas Myers', 18)}}的其他基金

Admin-Core-001
管理核心-001
  • 批准号:
    10942944
  • 财政年份:
    2023
  • 资助金额:
    $ 24.95万
  • 项目类别:
The Houston Center for Acquired Resistance Research (H-CARR)
休斯顿获得性耐药研究中心 (H-CARR)
  • 批准号:
    10518173
  • 财政年份:
    2022
  • 资助金额:
    $ 24.95万
  • 项目类别:
The Houston Center for Acquired Resistance Research (H-CARR)
休斯顿获得性耐药研究中心 (H-CARR)
  • 批准号:
    10830565
  • 财政年份:
    2022
  • 资助金额:
    $ 24.95万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10518174
  • 财政年份:
    2022
  • 资助金额:
    $ 24.95万
  • 项目类别:
The Houston Center for Acquired Resistance Research (H-CARR)
休斯顿获得性耐药研究中心 (H-CARR)
  • 批准号:
    10707142
  • 财政年份:
    2022
  • 资助金额:
    $ 24.95万
  • 项目类别:
Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancers
GOF TP53突变在头颈癌转移和免疫抑制中的功能作用
  • 批准号:
    10617289
  • 财政年份:
    2022
  • 资助金额:
    $ 24.95万
  • 项目类别:
Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancers
GOF TP53突变在头颈癌转移和免疫抑制中的功能作用
  • 批准号:
    10442206
  • 财政年份:
    2022
  • 资助金额:
    $ 24.95万
  • 项目类别:
Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancers
GOF TP53突变在头颈癌转移和免疫抑制中的功能作用
  • 批准号:
    10442206
  • 财政年份:
    2022
  • 资助金额:
    $ 24.95万
  • 项目类别:
The Houston Center for Acquired Resistance Research (H-CARR)
休斯顿获得性耐药研究中心 (H-CARR)
  • 批准号:
    10767096
  • 财政年份:
    2022
  • 资助金额:
    $ 24.95万
  • 项目类别:
Predicting and overcoming chemoradioresistance in p53-mutant head and neck cancer
预测和克服 p53 突变头颈癌的放化疗耐药性
  • 批准号:
    9433803
  • 财政年份:
    2014
  • 资助金额:
    $ 24.95万
  • 项目类别:

相似海外基金

Admin-Core-001
管理核心-001
  • 批准号:
    10942944
  • 财政年份:
    2023
  • 资助金额:
    $ 24.95万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10518174
  • 财政年份:
    2022
  • 资助金额:
    $ 24.95万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10493893
  • 财政年份:
    2022
  • 资助金额:
    $ 24.95万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10194364
  • 财政年份:
    2020
  • 资助金额:
    $ 24.95万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10401456
  • 财政年份:
    2020
  • 资助金额:
    $ 24.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了